OncoMatch/Clinical Trials/NCT06315257
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Is NCT06315257 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies PVX7 for cervical cancer.
Treatment: PVX7 — A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Biomarker criteria
Required: HPV positive
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IVA
advanced (stage IB1-IVA) HPV+ cervical cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: primary treatment (surgical resection, radiation, and/or platinum-based chemotherapy) — per NCCN guideline standard of care
have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months
Lab requirements
Blood counts
white blood cell count ≥ 3,000 cells/cu mm; lymphocyte number ≥ 500 cells/cu mm; absolute neutrophil count ≥ 1,000 cells/cu mm; platelets ≥ 90,000/cu mm; hemoglobin ≥ 9 g/dL
Kidney function
creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
Liver function
total bilirubin <1.5 X ULN, <3 x ULN if Gilbert's disease; AST and ALT <3 X ULN
Adequate organ function as defined by the following parameters: white blood cell count ≥ 3,000 cells/cu mm; lymphocyte number ≥ 500 cells/cu mm; absolute neutrophil count ≥ 1,000 cells/cu mm; platelets ≥ 90,000/cu mm; hemoglobin ≥ 9 g/dL; total bilirubin <1.5 X ULN, <3 x ULN if Gilbert's disease; AST and ALT <3 X ULN; creatinine < 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Alabama at Birmingham · Birmingham, Alabama
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06315257 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received primary treatment (surgical resection, radiation, and/or platinum-based chemotherapy).
Does this trial require HPV?
Yes, HPV positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB or IVA is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages